Taysha Gene Therapies’ (TSHA) Buy Rating Reaffirmed at Needham & Company LLC

Taysha Gene Therapies (NASDAQ:TSHA)‘s stock had its “buy” rating reiterated by analysts at Needham & Company LLC in a research note issued to investors on Thursday,Benzinga reports. They presently have a $6.00 price objective on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 419.48% from the stock’s current price.

Separately, Chardan Capital reiterated a “buy” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and an average price target of $6.63.

Taysha Gene Therapies Stock Down 3.7 %

Shares of TSHA stock traded down $0.05 during mid-day trading on Thursday, hitting $1.16. 253,281 shares of the stock traded hands, compared to its average volume of 2,689,015. Taysha Gene Therapies has a 52-week low of $1.05 and a 52-week high of $4.32. The stock has a market cap of $236.78 million, a P/E ratio of 1.83 and a beta of 0.96. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock’s fifty day moving average is $1.60 and its two-hundred day moving average is $1.85.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. The company had revenue of $2.02 million during the quarter, compared to analysts’ expectations of $2.05 million. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. Equities analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TSHA. Rhumbline Advisers boosted its position in Taysha Gene Therapies by 7.0% in the first quarter. Rhumbline Advisers now owns 205,462 shares of the company’s stock valued at $286,000 after buying an additional 13,383 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Taysha Gene Therapies by 26.4% in the 4th quarter. Wellington Management Group LLP now owns 585,594 shares of the company’s stock valued at $1,013,000 after acquiring an additional 122,402 shares during the last quarter. Squarepoint Ops LLC boosted its holdings in shares of Taysha Gene Therapies by 105.4% in the 4th quarter. Squarepoint Ops LLC now owns 211,842 shares of the company’s stock valued at $366,000 after acquiring an additional 108,719 shares during the last quarter. Rafferty Asset Management LLC acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter worth $436,000. Finally, ProShare Advisors LLC lifted its position in Taysha Gene Therapies by 32.3% during the fourth quarter. ProShare Advisors LLC now owns 59,076 shares of the company’s stock valued at $102,000 after purchasing an additional 14,418 shares during the period. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.